Yonsei Med J.  2005 Jun;46(3):394-398. 10.3349/ymj.2005.46.3.394.

Pretreatment with Ursodeoxycholic Acid (UDCA) as a Novel Pharmacological Intervention in Hepatobiliary Scintigraphy

• Jeong HJ
• Kim CG

• KMID: 1734075
• DOI: http://doi.org/10.3349/ymj.2005.46.3.394

Abstract

The purpose of this volunteer study was to investigate whether pretreatment with UDCA before the administration of 99mTc DISIDA affects the biliary excretion of the DISIDA, and whether it can shorten the total imaging time. Ten young, healthy volunteers (eight males, two females, mean age: 26.3 +/- 2.1 years) participated in the study. Hepatobiliary scintigraphies were performed twice per volunteer within three days, for the control and the UDCA-pretreated studies. In the control study, the gallbladder (GB) was observed first in four cases and the intestine was observed first in another four cases; in contrast, in the UDCA challenge study, the GB was observed first in eight cases. The quantitative results for the factors related to the GB differed significantly between the control and challenge studies. When the subjects were pretreated with UDCA, the time duration until visualization of the GB was shortened, and the maximum activity of the GB became more intense. In conclusion, UDCA pretreatment before hepatobiliary scintigraphy can shorten the total imaging time for evaluating functional obstructions of the cystic duct and increase the specificity of the process.

Keyword

Ursodeoxycholic acid; biliary system; scintigraphy

MeSH Terms

Adult
Biliary Tract/*radionuclide imaging
Female
Humans
Liver/*radionuclide imaging
Male
Radionuclide Imaging/*methods
Radiopharmaceuticals/*pharmacokinetics
Technetium Tc 99m Disofenin/*pharmacokinetics
Ursodeoxycholic Acid/*pharmacology

Figure

• 

  Fig. 1 Hepatobiliary scintigraphies of a volunteer untreated with UDCA (A) and pretreated with UDCA (B). After pretreatment with UDCA, the GB (arrow) is visualized first, then the intestine.

• 

  Fig. 2 Comparison of the time to visualization of the GB. The observation times of the GB converged without significant individual differences in eight cases of the UDCA pretreated hepatobiliary scintigraphies.

• 

  Fig. 3 Hepatobiliary scintigraphies from a volunteer with untreated UDCA (A) and pretreated UDCA (B). After pretreatment with UDCA, the maximum activity of the GB is more intense than that in the control study.

Reference

1. Shea JA, Berlin JA, Escarce JJ, Clarke JR, Kinosian BP, Cabana MD, et al. Revised estimates of diagnostic test sensitivity and specificity in suspected biliary tract disease. Arch Intern Med. 1994. 154:2573–2581.

2. Choy D, Shi EC, McLean RG, Hoschl R, Murray IP, Ham JM. Cholescintigraphy in acute cholecystitis: use of intravenous morphine. Radiology. 1984. 151:203–207.

3. Fink-Bennett D. Augmented cholescintigraphy: its role in detecting acute and chronic disorders of the hepatobiliary tree. Semin Nucl Med. 1991. 21:128–139.

4. Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr Gastroenterol Rep. 2002. 4:37–44.

5. Van de Meeberg PC, van Erpecum KJ, van Berge-Henegouwen GP. Therapy with ursodeoxycholic acid in cholestatic liver disease. Scand J Gastroenterol Suppl. 1993. 200:15–20.

6. Arrese M, Pizarro M, Solis N, Koenig C, Accatino L. Enhanced biliary excretion of canalicular membrane enzymes in ethynylestradiol-induced cholestasis. Effects of ursodeoxycholic acid administration. Biochem Pharmacol. 1995. 50:1223–1232.

7. Poupon R, Poupon RE. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmacol Ther. 1995. 66:1–15.

8. Poddar U, Bhattacharya A, Thapa BR, Mittal BR, Singh K. Ursodeoxycholic acid-augmented hepatobiliary scintigraphy in the evaluation of neonatal jaundice. J Nucl Med. 2004. 45:1488–1492.